Tag
The FDA is set to discuss reclassifying peptides for compounding, with telehealth companies like Mochi Health and Hims & Hers preparing to cash in on the anticipated regulatory shift, driven by political influence from HHS Secretary RFK Jr. and the GLP-1 boom.
The article explores how turnkey telehealth services enable virtually anyone—from established companies like JustAnswer to influencers—to sell GLP-1 weight loss drugs online, highlighting the rapid expansion of the digital health market and the role of infrastructure providers.
A journalist recounts being scammed by an online telehealth service that charged him for unwanted GLP-1 medications and refused refunds, highlighting a broader pattern of consumer fraud in the growing online weight-loss drug market.